Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.
The present study determined the pharmacokinetic profile of vancomycin in premature Malaysian infants. A one-compartment infusion model with first-order elimination was fitted to serum vancomycin concentration data (n = 835 points) obtained retrospectively from the drug monitoring records of 116 premature newborn infants. Vancomycin concentrations were estimated by a fluorescence polarization immunoassay. Population and individual estimates of clearance and distribution volume and the factors which affected the variability observed for the values of these parameters were obtained using a population pharmacokinetic modeling approach. The predictive performance of the population model was evaluated by visual inspections of diagnostic plots and nonparametric bootstrapping with replacement. Dosing guidelines targeting a value of > or =400 for the area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC(24)/MIC ratio) were explored using Monte Carlo simulation. Body size (weight), postmenstrual age, and small-for-gestational-age status are important factors explaining the between-subject variability of vancomycin pharmacokinetic parameter values for premature neonates. The typical population parameter estimates of clearance and distribution volume for a 1-kg premature appropriate-for-gestational-age neonate with a postmenstrual age of 30 weeks were 0.0426 liters/h and 0.523 liters, respectively. There was a 20% reduction in clearance for small-for-gestational-age infants compared to the level for the appropriate-for-gestational-age control. Dosage regimens based on a priori target response values were formulated. In conclusion, the pharmacokinetic parameter values for vancomycin in premature Malaysian neonates were estimated. Improved dosage regimens based on a priori target response values were formulated by incorporating body size, postmenstrual age, and small-for-gestational-age status, using Monte Carlo simulations with the model-estimated pharmacokinetic parameter values.
Lo
Yoke-Lin
YL
Department of Pharmacy, Faculty of Medicine, University of Malaya, Lembah Pantai, Kuala Lumpur, Malaysia. yllo@um.edu.my
van Hasselt
Johan G C
JG
Heng
Siow-Chin
SC
Lim
Chin-Theam
CT
Lee
Toong-Chow
TC
Charles
Bruce G
BG
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000097:blood*; D007236:Infant, Small for Gestational Age / Q000097:blood; D008296:Malaysia; D008954:Models, Biological; D009010:Monte Carlo Method; D012189:Retrospective Studies; D018805:Sepsis / Q000097:blood / Q000188:drug therapy; D018709:Statistics, Nonparametric; D014640:Vancomycin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*
D000900:Anti-Bacterial Agents; D014640:Vancomycin
Fetal Diagn Ther. 1993 Mar-Apr;8(2):109-13
8338622
Clin Pharmacol Ther. 2000 Apr;67(4):360-7
10801244
Antimicrob Agents Chemother. 2004 Apr;48(4):1159-67
15047516
J Antimicrob Chemother. 2008 Jun;61(6):1398-9
18349039
Clin Pharmacokinet. 2004;43(7):417-40
15139793
DICP. 1991 Jul-Aug;25(7-8):713-5
1949924
Am J Infect Control. 2007 Apr;35(3):183-9
17433942
Arch Dis Child Fetal Neonatal Ed. 2009 Mar;94(2):F144-8
18805822
Antimicrob Agents Chemother. 1990 Oct;34(10):1925-31
1963288
Biol Pharm Bull. 2003 Jun;26(6):876-9
12808304
Pediatr Infect Dis J. 2005 Nov;24(11):979-83
16282933
J Infect Chemother. 2005 Oct;11(5):259-61
16258825
Ther Drug Monit. 2008 Dec;30(6):709-16
19057373
Annu Rev Pharmacol Toxicol. 2008;48:303-32
17914927
Clin Pharmacokinet. 2004;43(13):925-42
15509186
Clin Pharmacokinet. 1997 Jul;33(1):32-51
9250422
J Antimicrob Chemother. 2006 Apr;57(4):589-608
16507559
Pediatrics. 1999 Apr;103(4):e49
10103341
Clin Pharmacokinet. 1996 May;30(5):329-32
8743333
Chest. 2006 Oct;130(4):947-55
17035423
Clin Infect Dis. 2009 Aug 15;49(4):507-14
19586413
J Antimicrob Chemother. 2002 Nov;50(5):713-8
12407128
Early Hum Dev. 2001 Jan;60(3):171-7
11146236
Br J Obstet Gynaecol. 1992 Apr;99(4):296-301
1581274
Ann Pharmacother. 2004 Oct;38(10):1702-6
15328391
J Pediatr. 1969 Jun;74(6):901-10
5781799
J Clin Microbiol. 2003 Oct;41(10):4660-5
14532199
Am J Perinatol. 1990 Oct;7(4):343-6
2222625
Am J Obstet Gynecol. 2003 May;188(5):1320-5
12748506
Ther Drug Monit. 2007 Jun;29(3):284-91
17529884
Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98
19106348
J Pharmacol Toxicol Methods. 1992 Aug;28(1):57-60
1392060
J Clin Pharmacol. 2001 Sep;41(9):927-34
11549096
Br J Clin Pharmacol. 2007 Jan;63(1):75-84
16869817
Pediatr Infect Dis J. 2009 May;28(5):398-402
19295465